**TEMPORARY REMISSION OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS AFTER INFECTION EPISODES**

*Takehiko Kobayashi*, *Toru Arai*, *Masaki Hirose*, *Tomomi Homma*, *Akiko Matsumuro*, *Chikatoshi Sugimoto*, *Masanori Kitaichi*<sup>1,5</sup>, *Masanori Akira*, *Yoshikazu Inoue*<sup>2</sup>

1 Department of Internal Medicine, 2 Clinical Research Center, 3 Department of Pathology, 4 Department of Radiology, National Hospital Organization, Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan; 5 Department of Pathology, National Hospital Organization Minami Wakayama Medical Center, Tanabe City, Wakayama, Japan

**ABSTRACT.** Pulmonary alveolar proteinosis (PAP) is a rare disease of unknown aetiology. Although resolution occurs in about 30% of autoimmune PAP (APAP) cases, its pathogenesis is not yet sufficiently understood. Two APAP cases at our institute showed remission following infectious episodes. Case 1: a 40-year-old female APAP patient suffered from herpes encephalitis and was treated with an antiviral drug. Her symptoms and radiological results resolved within two months of her recovery from the encephalitis. Case 2: A 53-year-old male current-smoker APAP patient was admitted for pneumonia. After treatment with antibiotics, his radiological results and symptoms improved. He experienced a similar resolution of APAP after another infectious episode two years later. Remission of APAP may occur following viral or bacterial infection. We hypothesise that remission of APAP is triggered by the induction of granulocyte-macrophage colony-stimulating factor (GM-CSF) following viral or bacterial infection. Further studies of APAP remission, and especially of the effects of GM-CSF induction, are needed. *(Sarcoidosis Vascul Diffuse Lung Dis 2017; 34: 85-90)*

**KEY WORDS:** pulmonary alveolar proteinosis, infection, remission

---

**Introduction**

Pulmonary alveolar proteinosis (PAP) is a rare disease of unknown aetiology, characterized by the accumulation of intraalveolar proteinaceous material that is rich in lipids and tests positive using the periodic acid-Schiff (PAS) stain (1). It has been shown that most idiopathic PAP patients have neutralizing autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). These cases are considered to be autoimmune PAP (APAP) (2). The pathophysiology of APAP is thought to be macrophage dysfunction caused by the neutralizing antibodies. The natural history of PAP can follow one of three pathways: spontaneous remission, stabilisation with persistent symptoms, or progressive deterioration (3). Spontaneous resolution occurs in about 30% of APAP cases (4). Some PAP cases partially improve following treatment of bacterial infections (5). However, the pathogenesis is uncertain and the course of APAP is unpredictable, with periodic flare-ups alternating with remission. Here we describe two APAP cases that showed remission in the disease severity, focusing on the relationship between the clinical course of infectious episodes and serum parameters.
Case presentation

Case 1

A 40-year-old female who never smoked was referred to our hospital with complaints of chronic cough and shortness of breath (Grade 1 of the modified Medical Research Council (MRC) scale (6)) over six months. Her physical examination revealed neither rales nor clubbed fingers. Her blood test results were as follows: white blood cell (WBC) count of 6.2 × 10^9/L (63.6% neutrophils, 27.3% lymphocytes, 7.8% monocytes and 1.3% eosinophils); haemoglobin of 14.8 g/dL; platelet count of 220 × 10^9/L; and serum lactate dehydrogenase (LDH) of 211 U/L. Her serum biomarkers for APAP (4) were elevated to high levels: she had carcinoembryonic antigen (CEA) levels of 18.1 ng/mL; cytokeratin fragment (CYFRA) 21-1 levels of 4.1 ng/mL; Krebs von den Lungen 6 (KL-6) of 17000 U/mL; surfactant protein (SP)-D levels of 168.0 ng/mL; and SP-A levels of 116.0 ng/mL (the normal cut-off levels for each biomarker were 5.0 ng/mL, 2.6 ng/mL, 500 U/mL, 110 ng/mL and 30 ng/mL, respectively). The chest radiograph showed bilateral infiltrative shadows, and a high-resolution computed tomography (HRCT) scan confirmed widespread, bilateral ground-glass attenuation (GGA) with thickened interlobular and intralobular septa, generally referred to as a ‘crazy paving’ pattern. The bronchoalveolar lavage fluid (BALF) was milky in appearance, and cytological evaluation showed that micronodular materials and large foamy macrophages were prominent. Anti-GM-CSF autoantibodies were detected in her serum (80.6 μg/mL). We therefore diagnosed her condition as APAP.

The patient’s arterial oxygen tension (PaO₂) under room air was 71.4 Torr. Her pulmonary function was severely disturbed, and her forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) were 58% and 42.7% of her predicted values, respectively. Her pulmonary symptoms did not improve spontaneously, and she was treated with GM-CSF inhalation from April to October 2007, according to the protocol of the phase II trial of GM-CSF inhalation in Japan (7). Thereafter, a whole lung lavage (WLL) was performed in April 2009, and a bronchoscopic lung lavage (left B1+2 and left B3) in October 2010. After the treatment by one segmental lavage with bronchoscopy in 2010, her pulse oximetry (SpO₂) has been stable around 92%-94% (room ambient), and no additional treatment had been needed from October 2010 to April 2013. The findings of chest X-ray during follow-up had been stable.

In April 2013, this patient had a high fever without worsening pulmonary symptoms. She developed refractory seizures and was diagnosed as having encephalitis associated with herpes simplex virus (HSV), based on a computed tomography (CT) head scan and the detection of viral deoxyribonucleic acid in her cerebrospinal fluid (CSF) via polymerase chain reaction. She was transferred to a neurosurgical hospital and received antiviral treatment. Along with remission in her exertional dyspnoea, her SpO₂ levels improved from 96% to 98%, serum levels of KL-6 decreased from 9837 U/mL to 4819 U/mL, and findings of her chest X-ray resolved. Her serum anti-GM-CSF autoantibody levels also decreased from 51.3 pg/mL to 31.0 pg/mL after this infectious episode (Table 1, Figure 1).

Case 2

A 53-year-old man was referred to our hospital in June 2005 with complaints of shortness of breath (modified MRC Grade 1 (6)). He was a current smoker who had smoked one pack per day from the age of 20. HRCT scans revealed subpleural heterogeneous GGA, including partial consolidations. His blood test results were: WBC count of 3.5 × 10^9/L (51.1% neutrophils, 38.1% lymphocytes, 8.1% monocytes, and 1.0% eosinophils); haemoglobin of 14.9 g/dL; platelet count of 148 × 10^9/L; and LDH of 147 U/mL. His serum biomarkers were elevated: he had a CEA of 11.4 ng/mL; CYFRA 21-1 of 11.1 ng/mL; KL-6 of 5050 U/mL; surfactant protein (SP)-D of 184 ng/mL; and SP-A of 95.7 ng/mL. Arterial blood gas analysis revealed that his PaO₂ under room air was 67.8 Torr in a supine position. His BALF was milky in appearance, and transbronchial lung biopsy specimens showed that the alveoli with preserved lung architecture were filled with PAS-positive microgranular materials. He was diagnosed as having APAP based on a positive test result for anti-GM-CSF antibodies in his serum (204.31 μg/mL). The patient was treated with GM-CSF inhalation (7) from December 2004 until March 2005. His alveolar-arterial oxygen difference decreased by more than 10 Torr and his pulmonary symptoms improved slightly. His SpO₂
Improvement of autoimmune pulmonary alveolar proteinosis

In January 2010, he was complaining of fever and a productive cough and was re-admitted to hospital. The productive cough worsened and was complicated by pneumonia. We did not perform BAL because we were afraid the lung disease of the patient might be worsened by the bronchoscopy procedure. Although we performed the sputum examination, we could not identify the pathogen of the disease. He received antibiotics empirically (ciprofloxacin, 200 mg, twice per day), and his cough improved in two weeks. HRCT scans showed that the GGA on both sides of his lungs, which suggested PAP, improved with respect to peripheral shadows after the treatment. Additionally, his serum levels of KL-6 decreased from 1097 U/mL to 1560 U/mL three months after the pneumonia episode. Although his SpO₂ levels (95%) did not change, his serum levels of KL-6 returned from 1097 U/mL to 1560 U/mL three months after the pneumonia episode.

**Analysis of serum GM-CSF and anti-GM-CSF autoantibodies**

We examined the relationship between serum levels of GM-CSF and anti-GM-CSF autoantibodies, retrospectively. We measured serum levels of free anti-GM-CSF autoantibodies, i.e. those not forming an immunocomplex with GM-CSF, using an enzyme-linked immunosorbent assay (ELISA), as previously reported (the detection limit of anti-GM-CSF autoantibodies: 0.5 μg/mL) (4,8). Serum GM-CSF was measured using a commercially available ELISA kit for GM-CSF (R&D SYSTEMS, Metropolis in USA) (Tables 1–3). Serum GM-CSF
levels in all three episodes were below the normal cut-off levels (7.8 pg/mL). Serum levels of anti-GM-CSF autoantibodies decreased after the diagnosis of the infections.

Discussion

There are two aspects to the association between APAP and infection. On one hand, the dysfunction of alveolar macrophages and neutrophils observed in APAP cases is thought to increase the risk of an opportunistic infection (9), including those by Nocardia (5), Mycobacterium (10), and Aspergillus (11) species. On the other hand, infections might affect the onset and progression of APAP (12-14). Indeed, infection might retard APAP, because remission of PAP after the treatment of aspergillosis has been observed (13). Based on the clinical courses by the precise observation of these cases, we believed the infectious episodes might be the triggers of remission of APAP. In case 1, three years from the previous WLL to the resolution of APAP after HSV infection were too long to consider the WLL improved APAP.
Whether infectious episodes improve or aggravate APAP activity might depend on the species of pathogenic organisms. With respect to *Aspergillus* infections, supernatant from aspergilli cultures has been shown to suppress macrophage function (15,16). Aspergilli stimulate SP-D production by type II alveolar epithelial cells *in vitro* (17). An *Aspergillus* infection might therefore cause a deterioration of APAP symptoms via these effects. The *Mycobacterium tuberculosis* 19-kDa lipoprotein inhibits expression of the Fcγ receptor (18). The elevation of serum levels of anti-GM-CSF autoantibodies caused by suppression of the internalisation of anti-GM-CSF autoantibodies via the receptor might lead to the deterioration of APAP when it is complicated with tuberculosis.

We speculated the remission of APAP after the infections described in our case studies might be triggered by GM-CSF induction following viral or bacterial infection. Serum GM-CSF was elevated in patients with community-acquired pneumonia, including viral infection and unidentified pathogens (19). We did not directly evaluate the alveolar macrophage function, but have shown that the serum levels of GM-CSF were not elevated in these two cases, and that the serum levels of anti-GM-CSF autoantibodies might have decreased following the infectious episodes. Uchida et al. reported that serum GM-CSF in APAP is more abundant than previously reported, and that it exists in a form of an immunocomplex (20). The GM-CSF, induced by infection, and anti-GM-CSF autoantibodies might have formed an immunocomplex in our two cases. As a result, the serum levels of free GM-CSF, i.e. that not forming an immunocomplex, were below cut-off levels at the onset of infection. Concentration of both types of GM-CSF, i.e. the free and immunocomplex forms, might have increased at the onset of infection, although measurement of the immunocomplex-forming GM-CSF is unfortunately impossible.

HSV encephalitis causes elevation of the levels of cytokines such as interleukin 6 (IL-6) and interferon-γ in the CSF. Moreover, a previous report suggests that production of serum GM-CSF leads to anti-HSV-1 immunity against the trans-neuronal spread of challenged HSV-1 within the visual system in animal models (21). The GM-CSF that is released from the CSF into the blood might influence the alleviation of APAP.

Previous reports have suggested a potential role for GM-CSF in the treatment of PAP (22-25). Remission in pulmonary symptoms following treatment with GM-CSF further reinforces the speculation that GM-CSF production is important in the pathogenesis of the remission of APAP following infectious episodes. We understand that we can't definitely conclude from only two cases.

In conclusion, these two case studies suggest that remission of APAP might be triggered by GM-CSF induction following viral or bacterial infection. It is therefore necessary to further investigate the role of GM-CSF and anti-GM-CSF autoantibodies using more cases involving APAP patients.

**Acknowledgements**

We acknowledge Koh Nakata (Niigata University Medical and Dental Hospital, Niigata, Japan) for technical support with the ELISA of anti-GM-CSF autoantibodies.
This study is supported by the grants of Practical Research Project for Rare/Intractable Disease of the Japan Agency for Medical Research and Development, AMED 15652554 (Y.I., T.A., A.M., M.K.), the grants from the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare (Y.I.), and the grants from the National Hospital Organization, Japan (Y.I., T.A.).

References

1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258: 1123-42.
2. Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009; 361: 2679-81.
3. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Med 2002; 166: 215-35.
4. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008; 177:752-62.
5. Yamaguchi S, Tamaguchi N, Tokunaga D, Sugita Y, Kawabata Y. A case of pulmonary alveolar proteinosis which initially deteriorated rapidly with exacerbation of pulmonary nodocardiosis, responded promptly to treatment of the pulmonary nodocardiosis. Nihon Kokyuki Gakkai Zasshi 2010; 48: 178-86.
6. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
7. Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181: 1345-54.
8. Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Med 2000; 162: 658-62.
9. Panunat AD, Kusne S, Blair JE, Seville MT, Vikram HR. Opportunistic infections in patients with pulmonary alveolar proteinosis. J Infect 2012; 65: 173-9.
10. Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore). 1994; 73: 103-9.
11. Matsuhashi T, Mori T, Urata A, Sakamoto H. Pulmonary alveolar proteinosis exacerbated by aspergillumina J Japan Soc Respir Endoscopy 2005; 27: 372-7.
12. Arai T, Inoue Y, Akira M, Nakata K, Kitaichi M. Autoimmune pulmonary alveolar proteinosis following pulmonary aspergillosis. Intern Med 2015; 54: 3177-80.
13. Lin KP, Sheng WH, Wang CP, Chang YL, Chang SC. Resolution of secondary pulmonary alveolar proteinosis following treatment of rhinocerebral aspergillus. Int J Infect Dis 2010; 14: 246-9.
14. Abdul R, Moodley YP, Phillips MJ. Pulmonary alveolar proteinosis associated with psoriasis and complicated by mycobacterial infection: successful treatment with granulocyte-macrophage colony stimulating factor after a partial response to whole lung lavage. Respirology 2004; 9: 419-22.
15. Murayama T, Amitani Y, Ikekami R, Nawada R, Lee WJ, Kuze F. Suppressive effects of Aspergillus fumigatus culture filtrates on human alveolar macrophages and polymorphonuclear leucocytes. Eur Respir J 1996; 9: 293-300.
16. Kamei K, Watanabe A, Nishimura K, Miyaji M. Cytotoxicity of Aspergillus fumigatus culture filtrate against macrophages. Nippon Ishinkin Gakkai Zasshi 2002; 43: 37-41.
17. Murayama T, Amitani R, Ikekami Y, et al. Effects of Aspergillus fumigatus culture filtrate on antifungal activity of human phagocytes in vitro. Thorax 1998; 53: 975-8.
18. Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and FcεR1 on human macrophages through Toll-like receptor 2. Infect Immun 2003; 71: 4487-97.
19. Michelow IC, Katz K, McCracken GH, Hardy RD. Systemic cytokine profile in children with community-acquired pneumonia. Pediatr Pulmonol 2007; 42: 640-5.
20. Uchida K, Nakata K, Suzuki T. Granulocyte macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 12: 2547-56.
21. van Iwaarden JF, Teding van Berkhout F, Whitsett JA, Oosting RS, van Golde LM. A novel procedure for the rapid isolation of surfactant protein A with retention of its alveolar-macrophage-stimulating properties. Biochem J 1995; 309: 551-5.
22. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Med 2001; 163: 524-31.
23. Barralclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56: 664-5.
24. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Med 2000; 161: 1143-8.
25. Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Med 2005; 171: 1142-9.